TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03557333

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INP104
Description: No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
Study: NCT02393898

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.

Intervention type: DRUG
Intervention: Carboplatin
Description: Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
Study: NCT04601311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-determination
Description: Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal support in goal-pursuing
Description: Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care.
Study: NCT01320709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam ( BAYl1902)
Description: Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam ( BAYl1902)
Description: Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo (i.e., 4 placebo capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam ( BAYl1902)
Description: Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
Study: NCT01386580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101
Description: IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101
Description: IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101 60 mg/m2 every 4 weeks
Description: IV every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101 50 mg/m2 every 3 weeks
Description: IV every 21 days
Study: NCT01937117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: PET will be performed at baseline and on day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg as a loading dose, then 420 mg every 3 weeks, IV
Study: NCT02810249

Intervention type: OTHER
Intervention: No intervention used
Study: NCT02629601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Rewards
Description: Vitality standard active rewards wellness program for physical activity promotion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rewards
Description: Vitality standard active rewards wellness program for physical activity promotion
Study: NCT02925832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Topical Fornix Nerve block anesthesia
Description: DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Topical Fornix Nerve block anesthesia
Description: DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.75% ropivacaine soaked sponges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5% bupivacaine soaked sponges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: For anaesthetising conjunctiva

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: For anaesthetising conjunctiva
Study: NCT02629601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rewards
Description: Vitality standard active rewards wellness program for physical activity promotion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rewards
Description: Vitality standard active rewards wellness program for physical activity promotion
Study: NCT02335957

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.

Intervention type: RADIATION
Group type: OTHER
Intervention: Irradiation
Description: Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
Study: NCT01653795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Unique: control device
Description: LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme: comparison device
Description: LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
Study: NCT02629601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lottery 1
Description: Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lottery 1
Description: Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lottery 2
Description: Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Broadcasting winners
Description: Participants are told how many individuals won the lottery during that week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Broadcasting winners
Description: Participants are told how many individuals won the lottery during that week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rewards Doubled
Description: Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
Study: NCT03064776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m-RESIST Patients
Description: A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
Study: NCT04043273

Intervention type: BEHAVIORAL
Intervention: Noninterventional characterization of patients expectations and preferences regarding their treatment
Description: Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
Study: NCT03064776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m-RESIST Caregivers
Description: A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
Study: NCT01903031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
Study: NCT03984318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
Study: NCT03659747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: - 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactrase
Description: - 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
Study: NCT02634879

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Change
Study: NCT02774226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Description: 12 week intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: 12 week intervention
Study: NCT01921257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cat-PAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03190876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variable drain usage
Description: Influence of drain usage on seroma formation rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variable drain usage
Description: Influence of drain usage on seroma formation rate
Study: NCT03044795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
Study: NCT00679614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramacet, naloxone
Description: Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramacet
Description: Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
Study: NCT01322152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, capecitabine
Description: Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
Study: NCT03750019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfying rehearsal task
Description: Participants rehearsed satisfying aspects of the lunchtime meal they just ate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dissatisfying rehearsal task
Description: Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral rehearsal
Description: Participants rehearsed their journey to campus that day.
Study: NCT03462745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuVein AV 300
Description: Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
Study: NCT03604744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD 0.1 mg per os, single dose
Study: NCT01903031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Description: Participants received EFV 600 mg daily with two or more NRTIs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV/r
Description: Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Participants received 300 mg of tenofovir in Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
Study: NCT00704678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: 1g tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 1.6 g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl
Description: 1.5 g tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 0.8 g tid
Study: NCT03896165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
Study: NCT04708106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco Flavor
Description: Ad libitum use of the RELX ENDS Tobacco Flavor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Menthol Flavor
Description: Ad libitum use of the RELX ENDS Menthol product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RELX ENDS Tobacco and Menthol Flavors
Description: Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
Study: NCT01634061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Study: NCT03204201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
Study: NCT04135742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive training includes memory, reasoning, processing speed and role playing, etc.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive training includes memory, reasoning, processing speed and role playing, etc.